OTCA19 – ”Screening for osteoporosis in the general population” final assessment and related documentation is now available
EUnetHTA is pleased to announce that the final project plan, final assessment, comments from the external experts and authors' answers, together with the final abstract and plain language summary for OTCA19 "Screening for osteoporosis in the general population'' are now
The public consultation of the draft methodological guideline “Practical considerations when critically assessing economic evaluations” is OPEN (deadline Oct. 11, 2019)
We are pleased to announce that, as of today, the draft methodological guideline "Practical considerations when critically assessing economic evaluations", produced within WP6 B2, has entered the public consultation phase. This consultation will be open until 11th October, 2019. Objective of the
OTCA22 – “Clinical utility of Point-of-care Tests (POCT) D-Dimer and Troponin” project plan and comments from external experts are now available.
EUnetHTA is pleased to announce that the project plan and and comments from external experts for the Other Technologies Collaborative Assessment OTCA22 "Clinical utility of Point-of-care Tests (POCT) D-Dimer and Troponin'' are now available for access. The final assessment report will
Minutes from 2018 EUnetHTA-EFPIA Technical Meeting now available
The minutes from the EUnetHTA-EFPIA Technical Meeting, held on 11th December 2018 at the Haute Autorité de Santé in Paris, are now available for access. Participants included attendees from both EFPIA and EUnetHTA, as well as the EMA and DG SANTE.
PTJA11 – EUnetHTA is pleased to announce the start of the next Pharmaceutical Joint Assessment.
PTJA11 addresses 'cefiderocol the for the treatment of infections due to aerobic Gram-negative bacteria in adult patients with limited treatment options’, submitted by Shionogi BV. We are delighted that AIFA and NOMA are authoring this assessment. We will be issuing an
The public consultation of the revision of the methodological guideline “Process of information retrieval for systematic reviews and health technology assessments on clinical effectiveness” is OPEN (deadline 27th September, 2019)
We are pleased to announce that, as of today, a revised version of the methodological guideline “Process of information retrieval for systematic reviews and health technology assessments on clinical effectiveness”, produced within WP6 B2, has entered the public consultation phase. This
PTJA07 – “Ustekinumab for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic, or have medical contraindications to such therapies” project plan is now available.
The final project plan of the assessment on ustekinumab is now available. The final assessment report will be published on 22nd October, 2019. Please access the final project plan at this link: PTJA07 - Final Project Plan
An Understanding of EUnetHTA HTA
The EUnetHTA Executive Board recently adopted the following Understanding of EUnetHTA HTA. This text is the result of several months of consultation with the project's board. The EUnetHTA Executive Board agreed that HTA in the context of EUnetHTA activities is understood
OTJA10 – Final Assessment report and related documents are now available
We are pleased to announce that the final assessment report for OTJA10 'Stool DNA testing for early detection of colorectal cancer', together with the fact check comments from manufacturers and comments from external experts including the replies of the author,
The EUnetHTA Prioritisation List (EPL) 2.0 is now published and available for access
EUnetHTA is pleased to announce the publication of the second iteration of the EPL. As part of the overarching Topic Identitication, Selection and Prioritisation (TISP) task group, the EPL is a valuable strategic tool for companies to identify the significant